Clinical trial
Safety and Efficacy of Pioglitazone as an Anti-inflammatory for the Treatment of…
NCT00322868 · University Hospitals Cleveland Medical Center, Other · Completed
Key facts
| NCT number | NCT00322868 |
|---|---|
| Title | Safety and Efficacy of Pioglitazone as an Anti-inflammatory for the Treatment of Cystic Fibrosis (CF) Lung Disease |
| Official title | A Pilot Study Assessing the Safety and Efficacy of Pioglitazone as an Anti-inflammatory Agent for the Treatment of CF Lung Disease in Patients With Cystic Fibrosis |
| Lead sponsor | University Hospitals Cleveland Medical Center, Other |
| Collaborators | Cystic Fibrosis Foundation |
| Status | Completed |
| Study type | Interventional |
| Conditions | Cystic Fibrosis |
| Intervention type | Drug |
| Interventions | pioglitazone |
| Enrollment | 21 |
| Start date | Apr 1, 2006 |
| Primary completion | Dec 1, 2006 |
| Completion | Apr 1, 2007 |
| First posted | May 8, 2006 |
| Last update posted | Feb 23, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: